CTOs on the Move


 
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.resmed.com
  • 9001 Spectrum Center Blvd
    San Diego, CA USA 92123
  • Phone: 858.836.5000

Executives

Name Title Contact Details
Urvashi Tyagi
Chief Technology Officer Profile
Sophia Mahmood
Director IT Strategic Initiatives Profile
Justin Condon
Director of Information Security Profile
Kaushik Ghoshal
Chief Technology Officer Profile
Kaushik Ghoshal
President, SaaS Business Unit Profile

Funding

ResMed raised $500M on 07/15/2019

Similar Companies

IRIS International

IRIS International, Inc. develops, manufactures and markets in vitro diagnostic (IVD) products, including IVD imaging systems based on neural network-based automated particle recognition (APR) software to enable high-speed digital processing to classify

Mark Ross and Co.

Mark Ross and Co., Inc is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthline Med

Healthline Med is a Baldwin Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smith and Nephew

Smith & Nephew is a global advanced medical technology business. We support healthcare professionals in more than 100 countries to improve the quality of life for their patients. Since 1856, when our founder T.J. Smith developed a new method for refining cod liver oil, and in World War One when his nephew led the supply of wound care products, to the present day, Smith & Nephew continues to pioneer health solutions. Through our market leadership positions in Sports Medicine, Trauma, Orthopaedic Reconstruction and Advanced Wound Management, our 16,000 employees continue to improve outcomes and expand access, constantly striving to create value for healthcare professionals, patients, payers and shareholders. Annual sales in 2016 were more than $4.6 billion. We are a constituent of the UK’s FTSE100 and our shares are traded on London Stock Exchange and through American Depository Receipts on the New York Stock Exchange   We have leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma.   We have almost 11,000 employees and a presence in more than 90 countries.   Annual sales in 2013 were more than $4.3 billion.   We are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)

Avita Medical

Avita Medical is a publicly listed regenerative medicine company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY). The company`s lead product, ReCell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA- registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use.